AL amyloidosis is characterized by the deposition of an excess of free light chains (FLCs) in the form of amyloid fibrils. These disrupt the structure and function of organs, including the kidney and heart.
Freelite® serum FLC laboratory tests, in combination with immunofixation of serum and urine, provide an efficient diagnostic screen for AL amyloidosis.
At diagnosis, the majority of patients have an abnormal Freelite® sFLC ratio.
Serum FLCs are an effective marker for monitoring AL amyloidosis, and are recommended by International guidelines.
